$1.79 0.00 (%) Synthetic Biologics Inc - NYSE Amex Equities

Jul. 27, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)

    Benzinga | Oct. 21, 2015 | 07:00AM EST
  2. Synthetic Biologics' Novel IBS-C Program Featured in American College of Gastroenterology Poster

    Benzinga | Oct. 20, 2015 | 15:31PM EST
  3. Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial

    Benzinga | Sep. 28, 2015 | 06:57AM EST
  4. Synthetic Biologics Says First Analysis Shows SYN-004 Protects Microbiome from IV Antibiotics Damage in Humanized Pig Model

    Benzinga | Sep. 21, 2015 | 06:59AM EST
  5. Insiders Are Buying Freeport McMoRan and Phillips 66

    GuruFocus | Sep. 11, 2015 | 16:00PM EST
  6. Benzinga's M&A Chatter for Wednesday August 26, 2015

    Benzinga | Aug. 26, 2015 | 19:25PM EST
  7. Mid-Day Market Update: Monday's Movers, China's Trade, Oil And More

    Benzinga | Aug. 10, 2015 | 12:29PM EST
  8. Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria

    Benzinga | Aug. 10, 2015 | 06:31AM EST
  9. Market Update: Thursday's Mid-Day Movers, Greece, Iran, IPOs And More

    Benzinga | Jul. 16, 2015 | 14:17PM EST
  10. Monday's Mid-Day Movers: Greece's Bank Shuts Down; Puerto Rico Unable To Pay Debts

    Benzinga | Jun. 29, 2015 | 13:28PM EST
  11. First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

    Benzinga | Jun. 12, 2015 | 06:59AM EST
  12. Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infect

    Benzinga | Dec. 22, 2014 | 06:59AM EST
  13. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  14. Earnings Scheduled For November 14, 2014

    Benzinga | Nov. 14, 2014 | 05:05AM EST
  15. Synthetic Biologics Issues UCLA Report of Prelim. Positive Topline Efficacy, Safety Results from Phase II Study of Trimesta

    Benzinga | Apr. 29, 2014 | 15:46PM EST
  16. Morning Market Movers

    Benzinga | Mar. 31, 2014 | 09:40AM EST
  17. Earnings Scheduled For March 31, 2014

    Benzinga | Mar. 31, 2014 | 05:03AM EST
  18. Intrexon: Living Better Through Synthetic Biology?

    IBD | Jan. 28, 2014 | 14:03PM EST
  19. Morning Market Losers

    Benzinga | Dec. 12, 2013 | 09:59AM EST
  20. Synthetic Biologics Prices 11.5M Share Offering at $1.00/Share

    Benzinga | Dec. 11, 2013 | 21:14PM EST
  21. Synthetic Biologics, Intrexon Initiate Development of Novel Biologics for a Subset of Patients Suffering from IBS

    Benzinga | Dec. 9, 2013 | 16:29PM EST
  22. Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes

    Benzinga | Dec. 7, 2013 | 20:06PM EST
  23. Intrexon IPO Prices High After Upsizing; Stock Soars

    IBD | Aug. 8, 2013 | 12:28PM EST
  24. Synodon Inc. - A Breakthrough Technology For Pipeline Safety

    GuruFocus | Jan. 28, 2013 | 10:46AM EST
  25. Synthetic Biologics Inc (SYN) CEO Jeffrey Scott Riley buys 2,900 Shares

    GuruFocus | Jan. 7, 2013 | 10:36AM EST
  26. Synthetic Biologics Inc (SYN) CEO Jeffrey Scott Riley buys 2,000 Shares

    GuruFocus | Jan. 4, 2013 | 11:08AM EST
  27. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman

    Benzinga | May. 11, 2012 | 01:02AM EST
  28. Adeona Becomes Synthetic Biologics

    Benzinga | Feb. 16, 2012 | 01:14AM EST
Trading Center